REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $451.53 million. The enterprise value is $596.48 million.
| Market Cap | 451.53M |
| Enterprise Value | 596.48M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 66.01 million shares outstanding. The number of shares has increased by 2.03% in one year.
| Current Share Class | 66.01M |
| Shares Outstanding | 66.01M |
| Shares Change (YoY) | +2.03% |
| Shares Change (QoQ) | +1.12% |
| Owned by Insiders (%) | 6.69% |
| Owned by Institutions (%) | 59.30% |
| Float | 57.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| Forward PS | 5.33 |
| PB Ratio | 5.04 |
| P/TBV Ratio | 6.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.86, with a Debt / Equity ratio of 3.49.
| Current Ratio | 2.86 |
| Quick Ratio | 2.70 |
| Debt / Equity | 3.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.91 |
Financial Efficiency
Return on equity (ROE) is -137.63% and return on invested capital (ROIC) is -97.79%.
| Return on Equity (ROE) | -137.63% |
| Return on Assets (ROA) | -21.20% |
| Return on Invested Capital (ROIC) | -97.79% |
| Return on Capital Employed (ROCE) | -54.00% |
| Weighted Average Cost of Capital (WACC) | 11.46% |
| Revenue Per Employee | $470,302 |
| Profits Per Employee | -$529,466 |
| Employee Count | 371 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.20% in the last 52 weeks. The beta is 1.13, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | -45.20% |
| 50-Day Moving Average | 8.41 |
| 200-Day Moving Average | 9.37 |
| Relative Strength Index (RSI) | 36.36 |
| Average Volume (20 Days) | 1,456,203 |
Short Selling Information
The latest short interest is 9.61 million, so 14.56% of the outstanding shares have been sold short.
| Short Interest | 9.61M |
| Short Previous Month | 7.93M |
| Short % of Shares Out | 14.56% |
| Short % of Float | 16.79% |
| Short Ratio (days to cover) | 7.07 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $174.48 million and -$196.43 million in losses. Loss per share was -$3.77.
| Revenue | 174.48M |
| Gross Profit | -78.42M |
| Operating Income | -164.15M |
| Pretax Income | -196.43M |
| Net Income | -196.43M |
| EBITDA | -148.78M |
| EBIT | -164.15M |
| Loss Per Share | -$3.77 |
Balance Sheet
The company has $105.52 million in cash and $250.46 million in debt, with a net cash position of -$144.95 million or -$2.20 per share.
| Cash & Cash Equivalents | 105.52M |
| Total Debt | 250.46M |
| Net Cash | -144.95M |
| Net Cash Per Share | -$2.20 |
| Equity (Book Value) | 71.77M |
| Book Value Per Share | 1.32 |
| Working Capital | 153.54M |
Cash Flow
In the last 12 months, operating cash flow was -$246.67 million and capital expenditures -$2.99 million, giving a free cash flow of -$249.67 million.
| Operating Cash Flow | -246.67M |
| Capital Expenditures | -2.99M |
| Depreciation & Amortization | 15.37M |
| Net Borrowing | n/a |
| Free Cash Flow | -249.67M |
| FCF Per Share | -$3.78 |
Margins
Gross margin is -44.95%, with operating and profit margins of -94.08% and -112.58%.
| Gross Margin | -44.95% |
| Operating Margin | -94.08% |
| Pretax Margin | -112.58% |
| Profit Margin | -112.58% |
| EBITDA Margin | -85.27% |
| EBIT Margin | -94.08% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.03% |
| Shareholder Yield | -2.03% |
| Earnings Yield | -55.05% |
| FCF Yield | -56.62% |
Analyst Forecast
The average price target for REGENXBIO is $23.58, which is 244.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $23.58 |
| Price Target Difference | 244.74% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 28.67% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -3.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.82 |
| Piotroski F-Score | 2 |